The investigators reported the results of a prospective, randomized, phase 3 trial studying the best individual therapy for women who have node-negative, estrogen-receptor‒positive (ER-positive) ...
Comprehensive review confirms that the Oncotype DX Breast Recurrence Score ® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity ...
Genomic Health announced results of three new Oncotype DX studies demonstrating the test's cost-effectiveness within the German and Hungarian healthcare systems, and Israeli data showing the test's ...
RFS stratified by BCT score in women ≤50 yrs with intermediate RS (16–25). Low BCT score predicted better RFS in all (P=0.007) (A) and non-chemo patients (P=0.020 ...
A mixed-methods feasibility study to evaluate and assess the clinical utility of multidisciplinary patient-centered information in breast cancer care. A novel non-invasive machine learning model for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback